Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.56 |
| ▸ | CASP7 | P55210 | 14/20 | 0.56 |
| ▸ | CASP1 | P29466 | 8/20 | 0.56 |
| ▸ | CASP9 | P55211 | 5/20 | 0.56 |
| ▸ | CASP4 | P49662 | 2/20 | 0.53 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033191 | 0.97 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL713780 | 0.97 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL4952116 | 0.93 | CASP3 (0.60) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL15939366 | 0.93 | CASP3 (0.64) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2034510 | 0.91 | CASP1 (0.67) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2043035 | 0.91 | CASP1 (0.67) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2038936 | 0.90 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL24213871 | 0.88 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP8 | |
| SCHEMBL17494194 | 0.88 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP8 | |
| SCHEMBL14646635 | 0.88 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210076956-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | Palo Alto Investors LP | 2021-03-18 | — | — | US | disclosed |
| US-10835134-B2 | Methods and compositions for restoring homeostatic capacity of a subject | PALO ALTO INVESTORS (US) | 2020-11-17 | — | — | US | disclosed |
| US-10799552-B2 | Methods for treating diabetic neurotherapy | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-10-13 | — | — | US | disclosed |
| EP-2560629-B1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2020-06-03 | — | — | EP | disclosed |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-05-05 | — | — | US | disclosed |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-07-18 | — | — | US | disclosed |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20190099467-A1 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2019-04-04 | — | — | US | disclosed |
| US-10149884-B2 | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2018-12-11 | — | — | US | disclosed |
| US-20130137642-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| WO-2013059791-A2 | METHODS AND COMPOSITIONS FOR PROMOTING AXON REGENERATION AND NERVE FUNCTION | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012061045-A2 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20110159004-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2011-06-30 | — | — | US | disclosed |
| US-7811832-B2 | Methods for preserving the viability of photoreceptor cells by anti-FAS-ligand/anti-FAS-receptor antibodies | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100074882-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-25 | — | — | US | disclosed |
| US-7592330-B2 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070287756-A1 | Methods and Compositions for Preserving the Viability of Photoreceptor Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-12-13 | — | — | US | disclosed |
| US-20070032427-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2007-02-08 | — | — | US | disclosed |
| US-20050129684-A1 | Methods and compositions for preserving the viability of photoreceptor cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099467-A1 | METHODS AND COMPOSITIONS FOR PRESERVING RETINAL GANGLION CELLS | GAP43, PDE6C, NGF | CASP3 10/4885CASP7 24/4885CASP1 85/4885 |
| US-20190216881-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | ALDH1A2, PDE6B, PDE6C | CASP3 18/4885CASP7 69/4885CASP1 140/4885 |
| US-10149884-B2 | Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells | ALDH1A2, PDE6B, PDE6C | CASP3 18/4885CASP7 69/4885CASP1 140/4885 |
| US-20190117724-A1 | METHODS FOR TREATING SPINAL CORD INJURY | NGF, GAP43, BDNF | CASP3 24/4885CASP7 45/4885CASP1 65/4885 |
| US-20130137642-A1 | METHODS AND COMPOSITIONS FOR PRESERVING PHOTORECEPTOR AND RETINAL PIGMENT EPITHELIAL CELLS | ALDH1A2, PDE6B, PDE6C | CASP3 18/4885CASP7 69/4885CASP1 140/4885 |
| US-10799552-B2 | Methods for treating diabetic neurotherapy | NGF, NTRK2, BDNF | CASP3 22/4885CASP7 67/4885CASP1 46/4885 |
| US-10617735-B2 | Methods and compositions for preserving retinal ganglion cells | GAP43, PDE6C, NGF | CASP3 10/4885CASP7 24/4885CASP1 85/4885 |
| US-10639345-B2 | Compositions for preserving photoreceptor cells, retinal pigment epithelial cells, or visual function | ALDH1A2, PDE6B, PDE6A | CASP3 33/4885CASP7 139/4885CASP1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.